Technology

By the end of this lesson, students will be able to:

• Account for how innovation and advances in technology shaped cultural and intellectual developments from 1914 to the present (Skill 5.B; LO M).
• Account for KC-4.3.II.B: how medical theories and technologies extended life but raised social and moral questions that eluded consensus and crossed religious, political, and philosophical perspectives.
• Connect the postwar antibiotic and vaccine revolutions, the molecular-biology revolution from the 1953 Watson-Crick discovery, the reproductive technologies (the contraceptive pill and IVF), the Human Genome Project, and the post-2012 CRISPR genome-editing revolution as a single linked phenomenon (Skill 5.B in direct practice).
• Account for the principal religious and philosophical responses, including the Catholic encyclicals (Humanae Vitae, Donum Vitae, Evangelium Vitae), and the European bioethics framework anchored by the 1997 Council of Europe Oviedo Convention.
• Account for the COVID-19 pandemic of 2020-2023 and the principal European mRNA vaccine response that the BioNTech-Pfizer collaboration produced.

Topic 9.12 covers postwar European medical theories and technologies and their substantial cultural-intellectual consequences. KC-4.3.II.B captures the central frame: medical theories and technologies extended life but raised social and moral questions that eluded consensus and crossed religious, political, and philosophical perspectives. The lesson is structured in four parts: the postwar life-extension revolution (antibiotics, vaccines, organ transplantation); the molecular-biology revolution (DNA structure through the Human Genome Project); the reproductive-technology revolution and its religious-ethical contestation; and the contemporary CRISPR genome-editing revolution and the COVID-19 pandemic response.

The postwar life-extension revolution. Three principal twentieth-century medical advances substantially extended European life expectancy: the antibiotic revolution; the vaccine revolution; and the development of organ transplantation and intensive-care medicine. The antibiotic revolution began with Alexander Fleming's accidental 1928 observation that the Penicillium mold produced an antibacterial substance; Howard Florey, Ernst Chain, and Norman Heatley's subsequent purification and clinical work at Oxford from 1939 onward produced the wartime mass-production effort (the United States and British production reached approximately 100 billion units per month by mid-1944) that substantially reduced wartime infectious-disease deaths. Streptomycin (Selman Waksman, 1943) treated tuberculosis; subsequent antibiotics across the postwar period (chloramphenicol 1948; tetracycline 1950s; erythromycin 1952; vancomycin 1953; methicillin 1959) produced the substantial late-twentieth-century reduction in infectious-disease mortality.

The vaccine revolution extended the immunization framework that the late-nineteenth-century Pasteur and Koch tradition had established. The principal twentieth-century vaccines: the inactivated polio vaccine (Jonas Salk, 1955); the oral polio vaccine (Albert Sabin, 1961); the measles vaccine (John Enders and Thomas Peebles, 1963); the mumps vaccine (Maurice Hilleman, 1967); the rubella vaccine (Stanley Plotkin, 1969); the combined MMR vaccine (1971); the hepatitis B vaccine (Maurice Hilleman, 1981); the HPV vaccine (2006). The cumulative European childhood-immunization coverage of approximately 95 percent across the postwar period substantially eliminated the principal childhood infectious diseases. Smallpox, the principal premodern killer disease, was declared eradicated by the World Health Organization on 8 May 1980 after the global vaccination campaign anchored by Donald Henderson's WHO Smallpox Eradication Programme of 1967-1980.

Organ transplantation and intensive-care medicine extended the postwar surgical capacity. The first successful human kidney transplant (Joseph Murray, Boston, 1954, between identical twins); the first successful heart transplant (Christiaan Barnard, Cape Town, South Africa, 3 December 1967, between an unrelated donor and recipient); the first successful liver transplant (Thomas Starzl, 1967); the development of immunosuppression (cyclosporine from 1972, in clinical use from 1983); the development of intensive-care medicine (the polio epidemics of the 1950s produced the principal postwar respirator and intensive-care framework; the first dedicated ICU was established in Copenhagen in 1953); and the development of medical imaging (the CT scanner of Godfrey Hounsfield, 1971; magnetic resonance imaging from the early 1980s; positron emission tomography). The cumulative effect was a substantial increase in European life expectancy from approximately 65 years in 1950 to approximately 80 years by 2020 (with substantial national variation: approximately 83 years in Switzerland, Italy, and Sweden by 2020; approximately 75 years in Bulgaria and Romania).

The molecular-biology revolution. James Watson and Francis Crick's discovery of the double-helix structure of DNA was the principal twentieth-century biological discovery. The 25 April 1953 paper "Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid" in Nature reported the principal finding (one page of text; the famous "It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material" line); Watson and Crick received the 1962 Nobel Prize in Physiology or Medicine alongside Maurice Wilkins. Rosalind Franklin's X-ray diffraction work at King's College London (the principal "Photograph 51" of B-form DNA from May 1952) had provided the principal experimental basis for the Watson-Crick model; Franklin had died of ovarian cancer in 1958 at age 37 and was thus ineligible for the 1962 Nobel Prize.

The subsequent molecular-biology revolution produced substantial genetic-engineering capacity. Recombinant DNA technology (Stanley Cohen and Herbert Boyer, 1972-1973) enabled the introduction of genes from one organism into another; the principal applications included the production of human insulin from genetically modified bacteria (commercialized 1982 by Genentech), human growth hormone, hepatitis B vaccine, and other therapeutic proteins. Polymerase chain reaction (Kary Mullis, 1985, Nobel Prize 1993) provided the principal DNA-amplification tool. The Human Genome Project (1990-2003), an international consortium principally funded by the United States National Institutes of Health and the United Kingdom Wellcome Trust, sequenced the approximately 3 billion base pairs of the human genome and identified approximately 20,000-25,000 protein-coding genes. The complete human genome (the GRCh38 reference) was substantially extended by the Telomere-to-Telomere Consortium completion in 2022. The cumulative genetic data have substantially shaped contemporary biomedical research, including the principal twenty-first-century cancer-genetic, pharmacogenomic, and rare-disease-diagnostic applications.

The CRISPR-Cas9 genome-editing revolution from 2012 substantially extended the molecular-biology capacity. The principal scientific work was conducted by Jennifer Doudna (University of California, Berkeley) and Emmanuelle Charpentier (then at Umea University, subsequently the Max Planck Unit for the Science of Pathogens in Berlin); their joint 2012 Science paper demonstrated that the bacterial Clustered Regularly Interspaced Short Palindromic Repeats system, with the Cas9 endonuclease, could be programmed to cut specific DNA sequences with substantial accuracy. Charpentier and Doudna received the 2020 Nobel Prize in Chemistry for the work. The principal subsequent applications include therapeutic genome editing (the November 2023 FDA approval of the Casgevy CRISPR therapy for sickle-cell disease, the first FDA-approved CRISPR therapy); agricultural applications (CRISPR-edited crops); and basic research applications. The November 2018 announcement by Chinese researcher He Jiankui that he had produced the first CRISPR-edited human babies (twin sisters Lulu and Nana, with the CCR5 gene edited as a putative HIV-resistance modification) produced substantial international ethical condemnation; He was sentenced to three years' imprisonment in December 2019 by a Chinese court for the unauthorized procedure.

Reproductive technology and the religious-ethical contestation. The reproductive-technology revolution (Topic 9.8 covered) raised some of the principal twentieth- and twenty-first-century social and moral questions. The combined oral contraceptive pill (FDA-approved 1960; UK 1961; France 1967) substantially reshaped European demographic and social life: by the late 1960s approximately 70 percent of British women under 30 used the pill; the Western European fertility rate declined from approximately 2.7 children per woman in 1960 to approximately 1.6 by 1980. The substantial Catholic theological response was Pope Paul VI's encyclical Humanae Vitae of 25 July 1968, which substantially against the recommendation of the Pontifical Commission on Birth Control rejected artificial contraception as "intrinsically dishonest." The encyclical produced substantial Catholic-theological dissent and substantial subsequent decline in Catholic-laity adherence to the formal contraceptive teaching across Western Europe.

The development of in-vitro fertilization (Robert Edwards and Patrick Steptoe; the first IVF baby Louise Brown was born at Oldham General Hospital on 25 July 1978) produced the principal subsequent reproductive-technology contests. Pope John Paul II's instruction Donum Vitae ("The Gift of Life") of 22 February 1987, issued by the Congregation for the Doctrine of the Faith under Cardinal Joseph Ratzinger (the future Pope Benedict XVI), rejected IVF, surrogate motherhood, and embryo experimentation. The substantial subsequent assisted-reproduction technologies (intracytoplasmic sperm injection 1992; preimplantation genetic diagnosis from the early 1990s; egg freezing from the 2010s) extended the IVF framework. The substantial European regulatory framework includes the British Human Fertilisation and Embryology Authority (established under the 1990 Human Fertilisation and Embryology Act), the German Embryo Protection Act of 1990 (substantially restrictive on embryo research), the French bioethics laws (substantially revised in 2004, 2011, and 2021), and the Italian Law 40 of 2004 (substantially restrictive; partially revised by the 2014 Constitutional Court decision and subsequent legislation).

The substantial subsequent end-of-life and abortion-rights debates have produced parallel European political-cultural contests. The Catholic encyclical Evangelium Vitae ("The Gospel of Life") of 25 March 1995 (Pope John Paul II) rejected abortion and euthanasia. The Dutch Termination of Life on Request and Assisted Suicide Act of 2002 (operational 1 April 2002) was the first European national law to authorize euthanasia; the Belgian Euthanasia Act followed on 28 May 2002 (operational 22 September 2002); the Luxembourg Law of 16 March 2009 followed; the Spanish Organic Law 3/2021 of 24 March 2021 produced the principal Mediterranean-Catholic-state authorization. The French and Italian end-of-life debates have produced more limited frameworks (the 2005 French Leonetti Law and the 2016 Claeys-Leonetti Law authorize "deep and continuous sedation" but not active euthanasia; the 2019 Italian Constitutional Court 242/2019 ruling authorized assisted suicide under specific conditions). The Swiss assisted-suicide framework (Article 115 of the Swiss Criminal Code, in force from 1942, permits assisted suicide for non-selfish motives) is the principal European destination for cross-border assisted-suicide tourism.

The contemporary technology revolution and the COVID-19 pandemic response. The post-2010 European biomedical position has substantially shaped subsequent global biomedical capacity. The principal European biomedical firms include the British-Swedish AstraZeneca; the Swiss Roche and Novartis; the British GlaxoSmithKline and AstraZeneca; the French Sanofi; the Danish Novo Nordisk (the principal global insulin and obesity-drug producer; market capitalization briefly the largest European company in 2024); and the German Bayer, BioNTech, CureVac, and Merck KGaA. The British Wellcome Trust, the German Max Planck Society, the French Pasteur Institute, and the Swiss-American CERN-related life-science institutions provide the principal European biomedical-research infrastructure.

The COVID-19 pandemic of 2020-2023, caused by the SARS-CoV-2 virus first identified in Wuhan, China, in December 2019, was the principal twenty-first-century global pandemic. The European death toll from COVID-19 reached approximately 2 million; the global death toll reached approximately 7 million (with substantial under-reporting in several jurisdictions producing higher excess-mortality estimates of approximately 18-27 million). The principal European public-health response included the substantial March-April 2020 lockdowns (the Italian lockdown of 9 March 2020 was the first major Western lockdown; the British, French, Spanish, German, and other lockdowns followed within days); the European Centre for Disease Prevention and Control coordination; the substantial economic-policy responses (the EU NextGenerationEU recovery fund of July 2020; the European Central Bank pandemic emergency purchase programme); the development of mRNA vaccines.

The mRNA vaccines were the principal European biomedical-technology contribution to the pandemic response. The German BioNTech firm (founded 2008 by Ugur Sahin, Ozlem Tureci, and Christoph Huber) had been developing mRNA cancer therapies; the BioNTech collaboration with the American Pfizer firm produced the BNT162b2 vaccine that received the first WHO emergency-use authorization on 31 December 2020 (after the British Medicines and Healthcare products Regulatory Agency approval on 2 December 2020 and the European Medicines Agency approval on 21 December 2020). The Oxford-AstraZeneca vaccine (developed at the University of Oxford under Sarah Gilbert and produced by AstraZeneca; approved December 2020); the Moderna mRNA vaccine (American, January 2021); and the Johnson and Johnson Janssen vaccine (American, March 2021) followed. The mRNA technology that anchored the BioNTech-Pfizer and Moderna vaccines was the product of decades of research by Hungarian-born American researcher Katalin Kariko (long working at the University of Pennsylvania; subsequently at BioNTech) and Drew Weissman, who received the 2023 Nobel Prize in Physiology or Medicine for the foundational work on modified-nucleoside mRNA. The mRNA technology has substantial subsequent applications across cancer therapy, infectious-disease vaccines, and other diseases.

The European bioethics institutional framework. The European institutional response to the substantial twentieth- and twenty-first-century medical-technology ethical questions has produced a multilayered framework. The Helsinki Declaration of the World Medical Association (adopted June 1964 in Helsinki, subsequently revised; provides the principal international medical-research ethics framework) and the Belmont Report of the United States National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (April 1979; foundational American medical-research ethics document) anchored the postwar medical-research ethics framework. The Council of Europe's Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (the Oviedo Convention; signed 4 April 1997 in Oviedo, Spain) is the principal European bioethics treaty. The convention prohibits genetic discrimination, the cloning of human beings (Additional Protocol of 12 January 1998), and the commercialization of the human body; the convention has 29 signatory states (including substantial member states of the EU and the broader Council of Europe but with notable non-signatories including the United Kingdom and Germany). The UNESCO Universal Declaration on the Human Genome and Human Rights of 11 November 1997 provided the parallel international framework. The substantial subsequent European bioethics committees, national-level bioethics laws, and the broader European bioethics academic-research literature have produced sustained institutional engagement with the twentieth- and twenty-first-century medical-technology questions.

The Skill 5.B argument. Topic 9.12's suggested skill is 5.B (Making Connections: account for the way one historical development or process is tied to another). The skill applies in two principal ways. First, students should connect the multiple medical-technology revolutions (antibiotics; vaccines; organ transplantation; molecular biology; reproductive technology; CRISPR genome editing; mRNA vaccines) as a single linked phenomenon despite their substantially different scientific bases and clinical applications. The cumulative effect substantially extended European life expectancy and substantially reshaped the European demographic, social, and cultural register. Second, students should connect the medical-technology revolutions to the broader Unit 9 narrative: the postwar economic miracle (Topic 9.2) generated the resources for sustained biomedical-research investment; the postwar welfare state (Topic 9.6) produced the institutional framework for universal medical-care provision; the long-running European feminist movement (Topic 9.8) was substantially shaped by the contraceptive and reproductive-technology revolutions; the postwar religious-life transformation (covered in Topic 9.14) substantially reflected the cumulative bioethical contests; and the post-1945 European integration project (Topic 9.10) produced the institutional framework that the Oviedo Convention and the European Medicines Agency anchor.

Three sources framing twentieth-century European medical technology: the foundational scientific paper, the principal religious response, and the European institutional bioethics framework.

1. (Causation, Skill 5.B) Connect the postwar antibiotic and vaccine revolutions to the molecular-biology revolution that the Watson-Crick 1953 discovery anchored. How did the cumulative twentieth-century medical technology extend European life expectancy?
2. (Causation) Account for KC-4.3.II.B: how did medical theories and technologies extend life but raise social and moral questions that crossed religious, political, and philosophical perspectives? Cite specific cases including contraception, abortion, IVF, end-of-life care, and CRISPR genome editing.
3. (Causation, Skill 5.B) Connect Pope Paul VI's Humanae Vitae (1968), Pope John Paul II's Donum Vitae (1987), and the Council of Europe Oviedo Convention (1997) as varied European responses to the postwar medical-technology revolution. How do religious and multilateral-institutional frameworks differ in their substantive register?
4. (Causation) Account for the post-2012 CRISPR genome-editing revolution and the substantial international response to the November 2018 He Jiankui case. What does the case reveal about the institutional limits and the substantive ethical contests that medical technology continues to produce?
5. (Causation, Skill 5.B) Connect the COVID-19 pandemic of 2020-2023 and the BioNTech-Pfizer mRNA vaccine response to the longer twentieth-century European biomedical trajectory. What does the 2020 European biomedical-technology achievement reflect about the cumulative postwar research investment?

Draft alignment — pending educator review. AP European History codes correspond to the official College Board Course and Exam Description (Effective Fall 2023, V.1). Statements below are paraphrased in the CountryReports voice; refer to the College Board's published CED for verbatim wording.